Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16589502 | 0.90 | HSD17B10 (0.47) | HSD17B10HPGDSMN1; SMN2USP2EPHX1 | |
| SCHEMBL15430147 | 0.90 | HSD17B10 (0.47) | HSD17B10HPGDSMN1; SMN2USP2EPHX1 | |
| SCHEMBL9977348 | 0.90 | HSD17B10 (0.47) | HSD17B10HPGDSMN1; SMN2USP2EPHX1 | |
| SCHEMBL15221624 | 0.89 | HPGD (0.46) | HSD17B10HPGDSMN1; SMN2USP2RECQL | |
| SCHEMBL16352852 | 0.89 | HPGD (0.46) | HSD17B10HPGDSMN1; SMN2USP2RECQL | |
| SCHEMBL30867255 | 0.85 | HSD17B10 (0.39) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL27516238 | 0.81 | HSD17B10 (0.42) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL27439612 | 0.81 | HSD17B10 (0.42) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL27443087 | 0.81 | HSD17B10 (0.42) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL7602070 | 0.80 | USP2 (0.46) | HSD17B10CHRM2CHRM1CHRM3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161278-A1 | 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| CN-101180292-A | 2-azetidinyl-4- (1H-pyrazol-3-ylamino) pyrimidines as inhibitors of insulin-like growth factor-1 receptor activity | ASTRAZENECA AB (SE) | 2008-05-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161278-A1 | 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity | IGF1R, IGFBP1, IGFBP2 | HSD17B10 4218/4885CHRM2 4839/4885CHRM1 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.